Immunotherapy is different: Implications for vaccine clinical trial design

Human Vaccines & Immunotherapeutics
Richard Simon

Abstract

Cancer Immunotherapetics differ fundamentally from most cancer therapies in that they involve manipulation of the immune system to induce an anti-tumor response. This fundamental difference results in differences in the pre-clinical and clinical development of immunotherapeutics. Even the regulatory culture of developing one drug at a time and demonstrating that it, when added to standard therapy, prolongs patient survival, is often not suitable for the development of effective immunotherapy regimens. In this commentary, we explore some of these differences and describe novel clinical trial designs which may be useful in immunotherapeutics regimen development.

References

Mar 1, 1997·Clinical Pharmacology and Therapeutics·L B Sheiner
Mar 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R M SimonJ A Berzofsky
May 24, 2005·Statistics in Medicine·Sally HunsbergerEdward L Korn
Jun 8, 2010·The New England Journal of Medicine·F Stephen HodiWalter J Urba
Sep 10, 2010·Journal of the National Cancer Institute·Axel HoosJedd Wolchok
Apr 19, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Steven A RosenbergMark E Dudley
Nov 9, 2011·Nature Reviews. Clinical Oncology·Donald A Berry
Jan 21, 2012·Science Translational Medicine·Mark M Davis
Jun 5, 2012·The New England Journal of Medicine·Suzanne L TopalianMario Sznol
Mar 27, 2013·The New England Journal of Medicine·Stephan A GruppCarl H June
Jul 20, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Osama E RahmaSamir N Khleif
Oct 9, 2015·Science Translational Medicine·Ilan R KirschRachael A Clark
Jul 15, 2016·The New England Journal of Medicine·Lisa A Carey, Eric P Winer

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Human Vaccines & Immunotherapeutics
Gareth RivallandThomas John
Expert Opinion on Therapeutic Targets
Ferdinando De VitaMichele Orditura
Cancer Biotherapy & Radiopharmaceuticals
R K Oldham
© 2022 Meta ULC. All rights reserved